Evidence map›Paper›PMID 34087553›Full record

SynthesisTransplantation reviews (Orlando, Fla.)2021

The association between severe or death COVID-19 and solid organ transplantation: A systematic review and meta-analysis.

Guangyu Ao, Yushu Wang, Xin Qi, Basma Nasr, Mulong Bao, Ming Gao, Ying Sun, Dili Xie

Abstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Transplantation reviews (Orlando, Fla.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Clinical outcome in solid organ transplant recipients affected by COVID-19 compared to general population: a systematic review and meta-analysis.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Real-world effectiveness of remdesivir in immunocompromised patients hospitalized due to SARS-CoV-2 Infection: Insights to inform pharmacy practice.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Remdesivir-Associated Survival Outcomes Among Immunocompromised Patients Hospitalized for COVID-19: Real-world Evidence From the Omicron-Dominant Era.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Remdesivir Reduced Mortality in Immunocompromised Patients Hospitalized for COVID-19 Across Variant Waves: Findings From Routine Clinical Practice.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Guangyu AoDepartment of Nephrology, Chengdu First People's Hospital, Chengdu, Sichuan, China.
Yushu WangDepartment of Cardiology, Chengdu First People's Hospital, Chengdu, Sichuan, China.
Xin QiDepartment of Neurology, the Affiliated Hospital of Southwest Jiaotong University & the Third People's Hospital of Chengdu, Sichuan, China.
Basma NasrDepartment of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Mulong BaoDepartment of Intensive Care Unit, Chengdu First People's Hospital, Chengdu, Sichuan, China.
Ming GaoDepartment of Cardiology, Chengdu First People's Hospital, Chengdu, Sichuan, China.
Ying SunDepartment of Geriatric Disease, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China. Electronic address: sunying@med.uestc.edu.cn.
Dili XieDepartment of Geriatric Cardiology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, Sichuan, China. Electronic address: xiedili1981@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe effect of solid organ transplantation (SOT) on the severity and mortality of coronavirus disease 2019 (COVID-19) remained controversial. There is still no consensus on whether solid organ transplantation (SOT) recipients with COVID-19 are at greater risk of developing severe or fatal COVID-19. Therefore, we conducted a systematic review and meta-analysis to investigate the association between SOT, severe COVID-19 illness, and mortality.

methodsA systemically comprehensive search in Pubmed, Embase, the Cochrane Library, Web of Science, and China National Knowledge Infrastructure was performed for relevant studies and articles. Consequently, we pooled the odds ratio (OR) from individual studies and performed heterogeneity, quality assessment and subgroup/sensitivity analysis.

resultsA total number of 15 articles with 265,839 participants were included in this study. Among the total number of participants, 1485 were SOT recipients. The meta-analysis results showed that transplant patients with COVID-19 were remarkably associated with a higher risk of intensive care unit admission than non-transplant patients (OR = 1.57, 95%CI: 1.07 to 2.31, P = 0.02). On the other hand, there were no statistically significant differences between SOT recipients and non-SOT recipients in mechanical ventilation need (OR = 1.55, 95%CI: 0.98 to 2.44, P = 0.06). In addition, we found that SOT recipients with COVID-19 had 1.40-fold increased odds of mortality than non-SOT recipients (OR = 1.40, 95%CI: 1.10 to 1.79, P = 0.007). Moreover, pooled analysis of adjusted results revealed that SOT recipients had a greater risk of mortality compared with non-SOT patients (HR = 1.54, 95%CI: 1.03 to 2.32, P = 0.037). LIMITATIONS: The main limitations in our study are attributed to the relatively small sample size, short follow-up period, and the fact that most of the studies included were retrospective in design.

conclusionsThe results of this study indicate that SOT recipients with COVID-19 had a more significant risk of COVID-19 severity and mortality than the general population.

Indexed as

PandemicsSARS-CoV-2COVID-19Global HealthHumansOrgan TransplantationSurvival RateTransplant RecipientsCOVID-19Meta-analysisMortalitySevereSolid organ transplantation

Identifiers

PMID34087553
PMCPMC8137345

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.